Liminatus Pharma, Inc. (NasdaqCM: LIMN)
Health Care · Biotechnology · US
$0.11
-19.57% today · -96.5% 1Y
Liminatus Pharma, Inc. (NasdaqCM: LIMN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.28M and employs 1 people.
Over the last twelve months the share price has lost 96.5%, trading between 0.10 and 4.85.
Tweenvest scores Liminatus Pharma, Inc. across four factors: quality 11/100. Its strongest factor is quality.
LIMN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.28M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.39
- Dividend yield
- —
- Beta (5Y)
- 0.74
- 52-week high
- $4.85
- 52-week low
- $0.10
- Avg volume (3M)
- —
- Shares outstanding
- 44.88M
- Employees
- 1
- Next earnings
- —
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
- ISIN
- US53271X2071
- Founded
- 2018
- Listed since
- May 1, 2025
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.